Dr Richard Warren, Senior Lecturer, University of Manchester and Honorary Consultant Dermatologist at Salford Royal NHS Foundation Trust and Lead Investigator for the clinical trial, said: “Psoriasis is a common life ruining condition with effects on patients’ quality of life similar to diseases such as cancer, heart attack, arthritis and depression. This clinical trial will investigate a new biological therapy for the treatment of psoriasis in what will be the largest trial of its type in the UK to date.”
The trial is designed to provide more information about this potential new treatment for moderate-severe psoriasis and will involve approximately 50 dermatology centres across the UK. Adults in the UK with psoriasis who have received treatment from a dermatologist can find out more about the clinical trial at www.psoriasisclinicaltrials.co.uk.
Bernadette, a 46 year old woman has been living with psoriasis since she was a child, said: “I was diagnosed with psoriasis at the age of 12. From that day my life changed for the worse. I hid my arms and legs as I was scared of what people would think. My confidence was shattered. My first marriage broke down due to heavy drinking and suicide attempts, I felt worthless. Psoriasis has affected me physically and mentally everyday.”
Psoriasis may profoundly affect all aspects of person’s social and personal lives as well as their work.
• There is no cure for psoriasis and over 70% of psoriasis patients report only low to moderate satisfaction with currently available treatment options2
• More than 5% of people with psoriasis experience depression and suicidal thoughts
• Up to 32% of people with moderate to severe psoriasis have been found to have problems with alcohol
• 20% of people with severe psoriasis take antidepressant medication
Psoriasis is a chronic inflammatory condition which is estimated to affect between 2% and 3% of the UK population – up to 1.8 million people. Plaque psoriasis is the most common type of psoriasis, accounting for 80% of cases and is characterised by thick and extensive skin lesions, known to cause itching, scaling and pain. More than one third of people with plaque psoriasis suffer from moderate-severe psoriasis, which can be difficult to treat. People are considered to have moderate-severe psoriasis when more than 10% of their body surface is affected, or when sensitive areas of the body are involved, such as hands or feet, which impacts on a person’s quality of life.
Notes for editors
For media enquiries please contact:
Novartis UK Pharmaceuticals Ltd
+44 (0)7876870473 (mobile)
Red Door Communications
+44 (0)20 8392 6933 (direct)
This clinical trial is being funded by Novartis Pharmaceuticals UK Limited and all materials relating to it are being provided by Novartis Pharmaceuticals UK Limited.
Novartis publishes the results of all clinical trials on its clinical trials website at www.novctrd.com.15
The foregoing release contains forward-looking statements that can be identified by terminology such as “on track,” “encouraging,” “committed,” “working to develop,” “ongoing,” “investigational,” “potential,” “will,” or similar expressions, or by express or implied discussions regarding this potential new treatment. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that this potential new treatment or any other dermatology products will be submitted or approved for sale in any market, or at any particular time. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.